GlobeNewswire Inc.T3·1mo ago
KPTI Karyopharm Therapeutics Inc.
XNAS
0.48
Delayed
Stock quote, options chain, IV rank, technicals, AI analysis, and institutional ownership. Iron condor setups Fibonacci levels Insider trading
Market data may be delayed, incomplete, or inaccurate. Not a recommendation to buy, sell, or hold any security. Verify quotes with your broker before trading. See Terms §17.
KPTI
$0.48
—
Key stats
$0.48
- 52-Week Range
- $0.31 – $10.99
- YTD
- -93.29%
- Straddle Price
- $0.50
- P/C Vol Ratio
- 0.14
- Market Cap
- $0.0B
- Open
- $0.51
- Day Range
- $0.42 – $0.52
- Volume
- 1,365,207
- Prev Close
- $0.52
Fair Value
+50.0% vs price
A blended fair-value estimate combining up to six valuation methods. Each method is weighted by how well it fits the company — DCF down-weights for unprofitable names; DDM only fires for steady dividend payers; comparables down-weight when peer multiples disagree.
- DCF (quality-aware) — projects free cash flow with a horizon that scales to business quality. True compounders (quality 6/6) get 10 years explicit + 10 years fade before terminal; cyclical/struggling names (quality 0-1) get a 5-year terminal cliff. Quality is scored from ROE, gross margin, growth, FCF margin, debt load, and FCF consistency — the same factors that drive market premium for compounders.
- Market-Implied Growth (in Model Inputs) — reverse-DCF that answers "what growth rate is the market pricing in?". Lets you sanity-check the deviation: if implied growth is plausible for the business, the model's bearish flag may be wrong; if implausible, the market may be over-extrapolating.
- DDM (Gordon Growth Dividend Model) — values the stream of future dividends. Only used when trailing yield ≥ 2% and dividend payments are stable — below that the dividend is a token payout and Gordon (which values only the dividend stream) systematically underprices growth names, so those route to DCF + comparables + market anchor instead.
- P/E, EV/EBITDA, P/B, P/S — applies the peer-group median multiple to this company's per-share metric. Peers come from the same set as the "Related symbols" card. Earnings/sales metrics are forward-tilted by the company's recent revenue growth (capped at 25%) so they're comparable to peers' growth-embedded multiples — mimics how analysts use NTM rather than TTM. Per-multiple weights are biased by company quality (e.g. P/B down-weighted for asset-light tech).
- Market Anchor (SMA50) — the 50-day moving average, weighted by recent trading-range stability (tighter Bollinger bands → higher weight). Captures information fundamentals miss (forward consensus, sentiment, supply/demand) — but only when recent trading is steady enough that the market has converged on a view. During wild breakouts or breakdowns the anchor's weight collapses.
- Options Expected (B-L 30d) — the risk-neutral expected stock price at 30-day options expiration, derived from the full implied-volatility surface via Breeden-Litzenberger (second derivative of call price wrt strike → implied PDF, then E[S_T]). Forward-looking, captures all options-implied information (smile, skew, term structure) in one number. Weighted by chain liquidity. SP500-only at present (pre-computed daily). Backtest evidence: adds modest alpha across most bucket × holding combos.
- Blended value — weighted average. Confidence reflects how many methods fired and how tight peer dispersion is.
- Deviation pill — green when blended FV ≥ 10% above current price (undervalued); red when ≥ 10% below; grey otherwise.
| 10-yr Treasury (rf) | 5.13% |
| Beta vs SPY | 1.41 |
| Cost of Equity (CAPM) | 12.90% (VRP-adj) |
| WACC | 5.60% |
| Volatility Risk Premium | +300.3pp (IV − HV30), ERP adj +50bps |
| Effective Tax Rate | 21.0% |
| Rev. Growth (YoY, DCF input) | -10.0% |
| DCF Horizon | 10 years explicit + fade |
| Free Cash Flow (TTM) | $-0.1B |
| Return on Equity (TTM) | 68.1% |
| Book / Price | -3178.0% |
| Gross Margin (TTM) | 95.9% |
| FCF Margin (TTM) | -44.6% |
| Quality Score | 2/6 — normal (10y DCF) |
| SMA 50 | $1.35 (Market Anchor value) |
| SMA 20 / Bollinger Mid | $0.65 |
| Bollinger Width / SMA20 | 31403.9% (drives anchor stability) |
| Net Debt | $0.2B |
| Market Cap | $0B |
Peers used for multiples: ALNY, DYN, GILD, ISRG, LLY, PODD, SYK, UNH
Blended Fair Value
$8.08
Deviation
+50.0%
| Method | Implied Price | Weight | Detail |
|---|---|---|---|
| DCF | n/a | 0% | |
| DDM (Gordon) | n/a | 0% | |
| Peer P/E | n/a | 0% | median 34.6× · 6 peers |
| Peer EV/EBITDA | n/a | 0% | median 28.2× · 7 peers |
| Peer P/B | n/a | 0% | median 8.5× · 8 peers |
| Peer P/S | $46.23 | 15% | median 6.3× · 7 peers |
| Market Anchor (SMA50) | $1.35 | 85% | stability 85% (BB-width) |
| Options Expected (B-L 30d) | n/a | 0% |
As of 2026-10-26 · updated
Related
About
- Industry (SIC)
- PHARMACEUTICAL PREPARATIONS (2834) · industry map
- Exchange
- XNAS
- Market Cap
- $0.0B
- Employees
- 228
- List Date
- 2013-11-06
- CIK
- 0001503802
- Next Earnings
- 2026-11-02 (After-Close)
- EPS Forecast
- ($1.15) (2 est.)
- Headquarters
- Newton, MA
- Homepage
- https://www.karyopharm.com
Karyopharm Therapeutics Inc is a commercial-stage pharmaceutical company focused on novel cancer therapies and dedicated to the discovery, development, and commercialization of drugs directed against nuclear export for the treatment of cancer and other diseases. The company conducts research focused on intracellular communication between the nucleus and cytoplasm and has developed small-molecule compounds that inhibit exportin 1 (XPO1), a nuclear export protein. It is focused on marketing XPOVIO (selinexor).
Summary
—
composite
—
No summary data available for this symbol yet.
Each spoke is this symbol's rank within its sector (0–100; the dotted ring marks the sector median at 50). Higher is more constructive for a long. One spoke — News sentiment — is an absolute reading, not a sector rank. Grayed spokes have no data. A fuller shape is a summary, not a recommendation.
Chart
Seasonality
| Month | '21 | '22 | '23 | '24 | '25 | '26 | Avg |
|---|---|---|---|---|---|---|---|
| Jan | -9.99% | 25.35% | 1.23% | -16.72% | -23.35% | -9.32% | -5.47% |
| Feb | -10.26% | 11.92% | -9.58% | 28.85% | -14.80% | 49.13% | 9.21% |
| Mar | -23.49% | -29.07% | 25.89% | 27.43% | -48.41% | -41.92% | -14.93% |
| Apr | -13.84% | -24.32% | -9.82% | -34.81% | 90.68% | 42.78% | 8.45% |
| May | -1.69% | -0.63% | -41.30% | -10.27% | -37.87% | 3.76% | -14.67% |
| Jun | 12.79% | -26.79% | -18.64% | -12.15% | 4.61% | -0.51% | -6.78% |
| Jul | -21.64% | -10.15% | 4.65% | 21.25% | -12.61% | -80.13% | -16.44% |
| Aug | -31.12% | 24.02% | -28.89% | -17.70% | 80.92% | 4.57% | 5.30% |
| Sep | -0.51% | 4.80% | -1.47% | 15.28% | -3.54% | -34.05% | -3.25% |
| Oct | -7.46% | -17.07% | -28.69% | 30.68% | -6.60% | -44.38%* | -12.25% |
| Nov | 19.42% | 12.31% | -2.06% | -6.43% | -7.41% | -- | 3.17% |
| Dec | -3.89% | -31.73% | 9.38% | -18.10% | 28.00% | -- | -3.27% |
| Total | -66.32% | -59.32% | -72.20% | -19.05% | -29.51% | -91.18% | -56.26% |
Technical Indicators
Quick-reference for reading the values below. Indicators combine to confirm a view — no single one is a trade signal on its own.
Trend Indicators
- SMA 20 / 50 / 200 — price above = uptrend, below = downtrend. SMA 50 crossing SMA 200 is the golden/death cross.
- EMA 12 / 26 — faster-reacting averages; 12 above 26 is short-term bullish.
- MACD — bullish when MACD > signal (green badge), bearish when below. Divergence from price often precedes reversals.
- ADX (14) — trend strength regardless of direction. <20 range, 20–25 weak trend, 25–50 trend, >50 strong trend.
- +DI / −DI — +DI > −DI favors bulls; the reverse favors bears. Read alongside ADX.
Momentum Oscillators
- RSI (14) — <30 oversold, >70 overbought. 40–60 is neutral; trending names can stay extreme.
- Stochastic %K / %D — <20 oversold, >80 overbought. %K crossing %D is an early momentum signal.
- Williams %R — inverted scale: <−80 oversold, >−20 overbought.
Oscillators work best in range-bound markets; in strong trends they give premature reversal signals.
Volume & Volatility
- Bollinger Bands — price at upper band = overbought, lower = oversold. Narrow bands (squeeze) often precede expansion.
- OBV — cumulative volume; rising OBV confirms uptrend, falling OBV confirms downtrend. Divergence from price is a warning.
- Vol SMA 20 / Vol ROC — today's volume vs. 20-day average. Positive ROC with price move = conviction.
- ATR / True Range — average daily $ move; sizing and stop-loss reference.
- HV 20 / 30 / 60 — realized (historical) volatility. Compare to IV on the options cards: IV > HV = rich premium.
Confluence matters: trend + momentum + volume agreeing carries far more weight than any single indicator. For how these feed the spread scanner score, see the algorithm docs →
Trend Indicators
SMA 20: $0.60
SMA 50: $1.32
SMA 200: $6.18
Current: $0.48
EMA 12: $0.52
EMA 26: $0.85
MACD: -0.3261 | Signal: 0.0664
BEARISH
ADX (14): 59.00
STRONG TREND
+DI: 14.27
−DI: 36.60
Momentum Oscillators
RSI (14): 29.84
OVERSOLD
Stoch %K: 48.18
Stoch %D: 37.37
Williams %R: -54.66
Volume & Volatility
BB Upper: $1.10
BB Lower: $0.09
NEUTRAL
OBV: -50,164,724
Vol SMA 20: 1,883,327
Vol ROC: 51.77%
ATR: $0.13
True Range: $0.10
HV 20: 249.0%
HV 30: 211.7%
HV 60: 162.3%
Data Summary
Data Points: 500
Last Updated:
Date Range: 2024-10-28T00:00:00 – 2026-10-26T00:00:00
AI Analysis
Here is the comprehensive stock analysis report for Karyopharm Therapeutics Inc. (KPTI):
Executive Summary
Overall Assessment: NEUTRAL (confidence level: 6)
Key Drivers:
- Technical indicators suggest a strong downtrend, with multiple moving averages pointing to a decline in price.
- Momentum oscillators indicate oversold conditions, which may lead to a short-term bounce.
- Options activity shows moderate volatility, with options market pricing a $0.93 move by expiration.
Primary Risks:
- Continued downward pressure due to negative sentiment and lack of positive catalysts.
- High-risk event horizon: earnings data not available; potential for surprise.
Recent News Sentiment Impact:
- Recent news headlines are mixed, with two positive articles (Sentinel trial and IMF) and one negative article (investor alert). The overall sentiment is neutral.
Technical Analysis
Trend Direction:
- Short-term: Downtrend
- Medium-term: Downtrend
- Long-term: Bearish
Support/Resistance Levels:
- Lower Bollinger Band: $1.80
- Upper Bollinger Band: $2.11
Momentum Signals:
- RSI (14): 25.08 (oversold)
- MACD: -1.12 / Signal: 0.25 / Histogram: -1.37 (bearish)
Volume Analysis:
- Volume SMA 20: 1578368.21
- On-Balance Volume (OBV): -31580022.66
- Volume Rate of Change: -5.56%
News & Sentiment Analysis
Recent Headlines Summary:
- INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Karyopharm Therapeutics Inc. - KPTI (GlobeNewswire Inc., 2026-08-04) NEGATIVE
- Menarini Group Reports Data from the Phase 3 SENTRY Trial of Selinexor (NEXPOVIO®) Plus Ruxolitinib in Myelofibrosis at The European Hematology Association (EHA) 2026 Congress (GlobeNewswire Inc., 2026-06-14) POSITIVE
- International Myeloma Foundation (IMF) Celebrates Myeloma Milestones for 2025 Myeloma Action Month (GlobeNewswire Inc., 2025-03-01) POSITIVE
- Glioblastoma Multiforme Treatment Market Size to Reach USD 5.68 Bn by 2033 (GlobeNewswire Inc., 2024-11-25) POSITIVE
- Down -12.14% in 4 Weeks, Here's Why Karyopharm Therapeutics Looks Ripe for a Turnaround (Benzinga, 2024-09-05) POSITIVE
- Advanced Melanoma Clinical Trial Pipeline Analysis - GlobeNewswire (GlobeNewswire Inc., 2024-07-08) POSITIVE
Sentiment Assessment:
- Aggregate news sentiment: NEUTRAL
Catalyst Identification:
- Upcoming events: Earnings data not available; potential for surprise.
Market Narrative:
- Recent news headlines suggest a mix of positive and negative sentiment, which may impact the stock price. The overall market narrative is neutral.
Risk & Volatility Assessment
Risk Assessment:
- Beta: 0.63 (vs SPY) - LOW risk
- Alpha: -0.59 - DEFENSIVE
- Correlation: 0.07 - HIGH risk
- Stock Volatility: 1.13 - MODERATE volatility
- Interpretation: Low volatility - stock moves less than market
Volatility Regime:
- Current vs historical volatility levels: HIGHER than normal
Options Market Signals:
- IV Rank: 55.2% (Medium) - shows if volatility is historically high/low
- Current IV: 443.9%
- Expected Move: $0.93 (21 DTE), 7-DTE: $0.93
- Volume Flow: 4,126 calls vs 8 puts
- Open Interest: 16,253 calls vs 34 puts
- Put/Call Volume Ratio: 0.00 (Bullish sentiment)
- Put/Call OI Ratio: 0.00
Downside Protection:
- Support levels and risk management considerations:
- Lower Bollinger Band: $1.80
- SMA 20: $1.95
Generated
News
All KPTI news →
GlobeNewswire Inc.T3·2mo ago
GlobeNewswire Inc.T3·4mo ago
GlobeNewswire Inc.T3·20mo ago
GlobeNewswire Inc.T3·23mo ago
BenzingaT3·26mo ago
GlobeNewswire Inc.T3·28mo ago
The Motley FoolT3·30mo ago
The Motley FoolT3·32mo ago
Zacks Investment ResearchT3·32mo ago
Showing 1–10 of 50
Page 1 of 5
Earnings History
19 of 22 under expected move
Avg Expected Move
41.10%
Avg Actual Move
5.56%
| Earnings Date | Timing | Expected Move | Actual Move | Ratio | Outcome |
|---|---|---|---|---|---|
| 2021-01-11 | After-Close | 9.32% | 4.29% | 0.46x | Within |
| 2021-05-03 | After-Close | 21.15% | 10.17% | 0.48x | Within |
| 2021-08-05 | After-Close | 19.33% | 6.91% | 0.36x | Within |
| 2021-11-03 | After-Close | 19.79% | 0.38% | 0.02x | Within |
| 2022-01-10 | After-Close | 40.85% | 8.76% | 0.21x | Within |
| 2022-05-05 | After-Close | 0.99% | 9.79% | 9.89x | Exceeded |
| 2022-08-04 | After-Close | 0.88% | 3.31% | 3.76x | Exceeded |
| 2022-11-03 | After-Close | 1.04% | 4.41% | 4.24x | Exceeded |
| 2023-01-09 | After-Close | 20.69% | 1.06% | 0.05x | Within |
| 2023-05-04 | After-Close | 20.86% | 2.17% | 0.10x | Within |
| 2023-08-02 | After-Close | 46.99% | 1.12% | 0.02x | Within |
| 2024-02-29 | After-Close | 21.74% | 2.16% | 0.10x | Within |
| 2024-05-08 | After-Close | 10.00% | 4.90% | 0.49x | Within |
| 2024-08-06 | After-Close | 17.05% | 3.43% | 0.20x | Within |
| 2024-11-05 | After-Close | 46.30% | 4.84% | 0.10x | Within |
| 2025-01-13 | After-Close | 260.53% | 5.89% | 0.02x | Within |
| 2025-05-12 | After-Close | 80.89% | 20.00% | 0.25x | Within |
| 2025-08-11 | After-Close | 134.62% | 6.63% | 0.05x | Within |
| 2025-10-08 | Pre-Market | 46.36% | 2.25% | 0.05x | Within |
| 2026-02-12 | After-Close | 34.96% | 4.03% | 0.12x | Within |
| 2026-05-14 | After-Close | 15.45% | 13.82% | 0.89x | Within |
| 2026-08-13 | Pre-Market | 34.48% | 1.97% | 0.06x | Within |
Earnings calendar: this week’s reports with expected vs actual moves →
KPTI Options Activity & IV Rank
Volatility Metrics
Current IV: —
7-DTE IV: —
Expected Move: $0.50
7-DTE Move: $0.50
Days to Exp: 25 (2026-11-20)
Options Flow
Call Volume: 359
Put Volume: 50
P/C Volume: 0.139
BULLISH
Call OI: 7,055
Put OI: 2,051
P/C OI: 0.291
Total OI: 9,106
ATM Options Pricing
ATM Call: $0.38
ATM Put: $0.12
Call %: 77.8%
Put %: 25.9%
Chain Summary
Chain Volume: 4,401
Chain OI: 47,240
Last Updated: 10/26/2026
Spread Scanner GPU
Each spread is ranked by a composite score built in three stages. Full documentation →
Stage 1 — Base Score (GPU scanner)
score = P(profit) × (credit / spread_width)
P(profit) from short leg delta (1 − |delta|), penalised above 85%. Credit uses mid-price to handle illiquid chains fairly.
Stage 2 — Skew Adjustment (±25% cap)
RR and BF (30-delta) from the persisted per-symbol skew snapshot — wing strikes picked by real greeks.delta, not a moneyness proxy. Put skew boosts bull puts, penalises bear calls. High butterfly boosts iron condors. Calendars are skew-neutral.
Stage 3 — Technical Overlay (±50% cap, 5 groups)
Group 1 · Directional Bias (±0.25)
- RSI <40 bullish / >60 bearish
- MACD crossover + histogram trend
- Price vs SMA 50 & SMA 200
Group 2 · Momentum (±0.10)
- Stochastic %K <20 / >80
- Williams %R <−80 / >−20
Group 3 · Volatility (up to −0.25 / +0.15)
- Blended ATR + straddle expected-move penalty
- Bollinger Band signal (+ counter-trend penalty)
- BB width — vol contraction boost for ICs
Group 4 · IV Regime (±0.15)
- IV rank ≥ 75 → strong boost for credit spreads
- IV rank < 25 → penalty (selling cheap vol)
Group 5 · Liquidity (penalty up to −0.10)
- Min open interest across all legs
- OI < 100 → −0.10 · OI < 500 → −0.05
score = base_score × skew_multiplier × tech_multiplier
Both multipliers are shown per spread. Beta is informational only — ATR already captures realized vol. Full algorithm documentation →
Enter a ticker to scan for optimal spread opportunities.
Evaluates all bull put, bear call, iron condor, and calendar spread combinations using GPU-accelerated analysis.
Dealer Positioning
TYPICAL γ
Estimated net dealer gamma is at the 28th percentile of this name's own daily history, within its typical range. This describes current positioning; it is not a forecast or a trading signal.
Gamma percentile
28%
vs own history
GEX tilt
-0.94
OI-weighted, today
Vanna tilt
-0.70
δ-sensitivity to IV
Charm tilt
+0.73
δ-decay vs time
Vanna tilt -0.70: the estimated dealer exposure leans negative, so the modeled hedge would shift noticeably if implied volatility changed.
Charm tilt +0.73: the estimated dealer exposure leans positive, so the modeled hedge would shift noticeably as time passes and options approach expiry.
? What is this?
· 3 ATM contracts, 0k total OI
Net dealer gamma is an estimate of the aggregate gamma held by options market makers across this name's option chain, weighted by open interest. Dealer positions aren't public, so it uses a standard simplifying assumption: dealers are treated as long the calls and short the puts that are open. Actual dealer books can differ.
Gamma percentile ranks today's estimate against this name's own daily history, from 0% (the lowest reading on record) to 100% (the highest). Raw gamma scales with how much open interest a chain carries, so it isn't comparable across names; the percentile is. The badge marks the bottom 20% as low and the top 20% as high.
Tilts run from −1 to +1 and show how lopsided the estimated dealer exposure is. GEX tilt compares call gamma with put gamma. Vanna tilt describes how the hedge would shift if implied volatility changed, and charm tilt how it would shift with the passage of time.
This card describes estimated positioning and where it sits historically. It is not a forecast of price direction or volatility and not a trading signal. Market-wide view: Dealer positioning screener.
Skew (Wing IV − ATM IV)
DTE:
Wing Δ:
Wing vs ATM
IV(put wing) − IV(ATM), in vol pointsHow much the OTM put trades above (or below) the at-the-money strike. Measures the height of the put-side tail relative to ATM — i.e. how expensive crash insurance is on this name.
- Positive (typical) — wing IV > ATM IV. Standard equity put skew: portfolios bid up crash protection, so OTM puts trade richer than ATM.
- Near zero or negative (unusual) — wing IV ≤ ATM IV. Flat or inverted put side. Common when there's no fear demand, in tightly mean-reverting names, or right after an earnings catalyst clears.
- Percentile vs own 3-yr history: high = wings rich (good time to sell wing premium); low = wings cheap (good time to buy protection).
- Not directional — high or low wings don't predict up or down moves. It's a price tag on tail insurance, not a forecast.
Risk Reversal
IV(call wing) − IV(put wing), equal delta on each sideWhich side of the smile is the market paying up for? Measures the tilt of the surface — call skew vs put skew at matched deltas.
- Negative (typical) — puts richer than calls. Standard equity behavior: hedging demand makes puts carry a premium. Most large-caps sit in the −1 to −5 vol-point range.
- Strongly negative (< −5 pts) — heavy downside hedging, elevated fear, or an upcoming catalyst (earnings, FDA, macro event). Worth flagging.
- Positive — calls richer than puts. Unusual for equities; signals bullish momentum, short-squeeze positioning, or takeover/M&A speculation.
- Near zero — symmetric surface. Market sees roughly equal up/down risk. Rare for large-caps; more common in commodities and FX.
Reading them together
Wing-vs-ATM tells you how expensive the tails are. Risk Reversal tells you which side is favored. Combined:
- High wing percentile + deeply negative RR → strong put bid; stress or major event priced in. Owning protection costs a premium; selling put premium is dangerous.
- Low wing percentile + near-zero RR → complacency; insurance cheap and balanced. Good environment to add cheap downside hedges.
- Positive RR + elevated wings → call-side fear-of-missing-out; common in squeeze setups. Upside calls expensive, downside puts not bid.
14 DTE / 10d
—
—
pts
EXTREME
as of Oct 26 · No data
30 DTE / 10d
—
—
pts
EXTREME
as of Oct 26 · ATM 1017.7% / Wing —
Extreme reading.
Historically these have been contrarian — on the small set of observed earnings-day cases, large negative wing-vs-ATM gaps (calls pricing much richer than puts at the same delta) preceded sharp drops in the underlying within 1-12 days. Not financial advice and the dataset is small.
Percentile is the rank of today's reading within ~3 years of this symbol's own history. High percentile = wings are rich relative to history; not a directional signal. Skew is read off the chain in real time, not from CBOE SKEW.
Volatility Surface
Enter a ticker to render the implied volatility surface.
Volatility Smile
Enter a ticker to render the implied volatility smile.
IV Rank (7 DTE)
IV Rank (30 DTE)
Straddle Price (30 DTE)$0.50Oct 26
Beta Analysis
Risk Metrics
Beta: 0.3513
Alpha: -147.74%
Correlation: 0.0349
R-Squared: 0.1%
Stock Volatility: 128.4%
Market Volatility: 12.7%
Analysis Details
Benchmark: SPY
Data Points: 251
Period: 252 trading days
Data Points: 251
Period: 252 trading days
Interpretation:
Low volatility - stock moves less than market
Low volatility - stock moves less than market
Beta & Alpha Over Time
Notable investors who own KPTI
3 of 37 tracked investors
| Investor | Value | Share of their portfolio | Rank | Q/Q shares | Source |
|---|---|---|---|---|---|
| Millennium Management Hedge fund Izzy Englander | $3.0M | #2356 of 3716 | -27.3% | 13F | |
| Renaissance Technologies Hedge fund Jim Simons | $1.1M | #2285 of 3138 | +2.7% | 13F | |
| Citadel Hedge fund Ken Griffin | $509K | #4447 of 6285 | new | 13F |
Hedge funds, activists, holding companies and family offices we track, from their latest 13F (quarter-end value) and Form 4 filings in the last 3 years. Family offices · all institutions
KPTI Institutional Ownership (13F)
Latest filings — 2026-09-30
? 13F Guide
Diluted shares outstanding: 20,075,750 (as of 2026-06-30)
Institutional managers with $100M+ AUM file Form 13F-HR quarterly, due 45 days after quarter end. Holdings are reported gross at quarter-end market value — they are a snapshot, not a real-time position.
- Shares — long equity positions in this name, aggregated across share classes.
- Calls / Puts — notional value of long call / put exposure where this ticker is the underlying.
- % of Float — holder's reported shares divided by the latest diluted shares outstanding. Sums above 100% indicate large custodian / prime broker positions where the same shares are reported by multiple filers.
- Custodian badge — filers with more than 5,000 holdings are typically broker-dealers / custodians reporting customer-held shares, not active managers.
Each filer is counted once at its latest 13F-HR filing. New filings are ingested on a weekly cadence.
10 filers$13.74M notional
| # | Filer | Notional Value | % of Total | Period |
|---|---|---|---|---|
| 1 | Susquehanna International Group, LLP Custodian | $4.74M | 34.47% | 2026-06-30 |
| 2 | Caption Management, LLC | $2.79M | 20.31% | 2026-06-30 |
| 3 | Tetragon Partners GP Ltd | $2.45M | 17.80% | 2026-06-30 |
| 4 | GROUP ONE TRADING LLC Custodian | $1.15M | 8.36% | 2026-06-30 |
| 5 | SILVERBACK ASSET MANAGEMENT LLC | $977.00K | 7.11% | 2026-06-30 |
| 6 | DLD Asset Management, LP | $780.98K | 5.68% | 2026-06-30 |
| 7 | Citadel Advisors LLC Custodian | $509.99K | 3.71% | 2026-06-30 |
| 8 | Jane Street Group, LLC Custodian | $286.26K | 2.08% | 2026-06-30 |
| 9 | JPMorgan Chase & Co Custodian | $63.54K | 0.46% | 2026-06-30 |
| 10 | Simplex Trading, LLC Custodian | $977 | <0.01% | 2026-06-30 |
9 filers$3.97M notional
| # | Filer | Notional Value | % of Total | Period |
|---|---|---|---|---|
| 1 | DLD Asset Management, LP | $989.62K | 24.94% | 2026-06-30 |
| 2 | Caption Management, LLC | $903.73K | 22.78% | 2026-06-30 |
| 3 | J. Goldman & Co LP | $660.45K | 16.65% | 2026-06-30 |
| 4 | Susquehanna International Group, LLP Custodian | $594.99K | 15.00% | 2026-06-30 |
| 5 | Millennium Management LLC Custodian | $351.72K | 8.87% | 2026-06-30 |
| 6 | Jane Street Group, LLC Custodian | $232.53K | 5.86% | 2026-06-30 |
| 7 | Citadel Advisors LLC Custodian | $133.85K | 3.37% | 2026-06-30 |
| 8 | Simplex Trading, LLC Custodian | $86.95K | 2.19% | 2026-06-30 |
| 9 | GROUP ONE TRADING LLC Custodian | $13.68K | 0.34% | 2026-06-30 |
KPTI Insider Trading (Form 4)
Latest: 2026-10-19Form 4 filings — insider beneficial-ownership changes by officers, directors, and 10%+ holders. Filed within 2 business days of transaction.
| Filed | Reporter | Role | Action | Shares | Avg Price | Net $ | Link |
|---|---|---|---|---|---|---|---|
| 2026-10-19 | Kristin Abate | Chief Accounting Officer | Sell (S) | −4,788 | $0.34 | -$1.6K | EDGAR |
| 2026-10-02 | Kristin Abate | Chief Accounting Officer | Sell (S) | −378 | $1.19 | -$450 | EDGAR |
| 2026-09-02 | Kristin Abate | Chief Accounting Officer | Sell (S) | −19 | $2.02 | -$38 | EDGAR |
| 2026-07-30 | Stuart Poulton | EVP, Chief Development Officer | Sell (S) | −189 | $7.10 | -$1.3K | EDGAR |
| 2026-05-26 | Garen G Bohlin | Director | Award (A) | +15,508 | — | EDGAR | |
| 2026-05-26 | Christy J. Oliger | Director | Award (A) | +15,508 | — | EDGAR | |
| 2026-05-26 | Deepika Pakianathan | Director | Award (A) | +15,508 | — | EDGAR | |
| 2026-05-26 | Chen Schor | Director | Award (A) | +15,508 | — | EDGAR | |
| 2026-05-26 | Barry E Greene | Director | Award (A) | +15,508 | — | EDGAR | |
| 2026-05-26 | Zhen Su | Director | Award (A) | +15,508 | — | EDGAR | |
| 2026-05-15 | Michael Mano | EVP, CLO&Secretary | Mixed | +434 | $9.50 | -$2.5K | EDGAR |
| 2026-05-15 | Kristin Abate | Chief Accounting Officer | Mixed | +68 | $9.50 | -$504 | EDGAR |
| 2026-05-15 | Stuart Poulton | EVP, Chief Development Officer | Mixed | +493 | $9.50 | -$3.8K | EDGAR |
| 2026-05-15 | Sohanya Roshan Cheng | EVP & Chief Commercial Officer | Mixed | +623 | $9.50 | -$3.1K | EDGAR |
| 2026-05-15 | Reshma Rangwala | EVP & Chief Medical Officer | Mixed | +539 | $9.50 | -$3.9K | EDGAR |
Codes: P = open-market purchase · S = open-market sale · A = grant/award · M = option exercise · F = tax withholding at vest · G = bona-fide gift · D = disposition to issuer · J = other (described in filing footnote — typically 401(k), trust, inheritance) · W = will/inheritance. Only P / S codes carry directional signal.
KPTI Insider Holdings
14 insiders · @ $0.48
Officers, directors, and 10%+ owners who have filed a Form 4 in the past two years, ranked by current disclosed exposure (shares × today's price). Shares are direct + indirect (via trusts / LLCs / spouse). Excludes unvested RSU and option grants — those aren't beneficially owned until vest.
| # | Insider | Role | Shares | Disclosed Exposure | Lifetime OM Net | Filings | Last Filed |
|---|---|---|---|---|---|---|---|
| 1 | Richard A. Paulson | President and CEO | 269,747 | $130.0K | -$875.9K | 51 | 2026-05-15 |
| 2 | Sohanya Roshan Cheng | EVP & Chief Commercial Officer | 108,264 | $52.2K | -$162.0K | 18 | 2026-05-15 |
| 3 | Stuart Poulton | EVP, Chief Development Officer | 94,632 | $45.6K | -$146.7K | 19 | 2026-07-30 |
| 4 | Michael Mano | EVP, CLO&Secretary | 94,398 | $45.5K | -$107.8K | 15 | 2026-05-15 |
| 5 | Lori Macomber | EVP, CFO & Treasurer | 85,105 | $41.0K | -$10.2K | 4 | 2026-02-04 |
| 6 | Reshma Rangwala | EVP & Chief Medical Officer | 56,829 | $27.4K | -$144.2K | 15 | 2026-05-15 |
| 7 | Deepika Pakianathan | Director | 30,795 | $14.8K | $1.40M | 19 | 2026-05-26 |
| 8 | Kristin Abate | Chief Accounting Officer | 18,616 | $9.0K | -$16.9K | 14 | 2026-10-19 |
| 9 | Garen G Bohlin | Director | 18,517 | $8.9K | $81.3K | 15 | 2026-05-26 |
| 10 | Barry E Greene | Director | 16,415 | $7.9K | $87.9K | 16 | 2026-05-26 |
Lifetime OM Net = signed sum of open-market buys (P) and sells (S) over their career; excludes grants, tax withholdings, and dispositions to issuer. A large negative number is normal for long-tenured executives — they've sold compensation grants over many years.
KPTI Board & Officers
As of SEC filings through Oct 19, 2026Directors 7
- Barry E Greene · since Nov 5, 2013
- Deepika Pakianathan · since Nov 5, 2013
- Garen G Bohlin · since Nov 5, 2013
- Richard A. Paulson · since Feb 26, 2020
- Christy J. Oliger · since Aug 28, 2020
- Chen Schor · since Nov 25, 2020
- Zhen Su · since Aug 31, 2023
Officers 7
- Richard A. Paulson · President and CEO · listed since May 2021
- Lori Macomber · EVP, CFO & Treasurer · since Jan 3, 2025
- Reshma Rangwala · EVP & Chief Medical Officer · since Apr 19, 2022
- Stuart Poulton · EVP, Chief Development Officer · since Aug 15, 2022
- Sohanya Roshan Cheng · EVP & Chief Commercial Officer · listed since Sep 2022
- Kristin Abate · Chief Accounting Officer · since Nov 6, 2024
- Michael Mano · EVP, CLO&Secretary · listed since Feb 2026
Changes in the last 10 years (42)
| Feb 3, 2026 | Michael Mano listed as EVP, CLO&Secretary (previously SVP, General Counsel&Secretary) in SEC filings |
| Sep 5, 2025 | The company announced the departure of Mansoor Raza Mirza from the board in an SEC filing |
| Jan 3, 2025 | Lori Macomber became EVP, CFO & Treasurer |
| Nov 6, 2024 | Kristin Abate became Chief Accounting Officer |
| Aug 26, 2024 | The company announced the departure of Michael Mason as EVP, CFO & Treasurer in an SEC filing |
| Aug 31, 2023 | Zhen Su became a director |
| Sep 1, 2022 | Sohanya Roshan Cheng listed as EVP & Chief Commercial Officer (previously Chief Commercial Officer) in SEC filings |
| Aug 15, 2022 | Stuart Poulton became EVP, Chief Development Officer |
| Apr 19, 2022 | Reshma Rangwala became EVP & Chief Medical Officer |
| Mar 28, 2022 | The company announced the departure of Sharon Shacham as Chief Scientific Officer in an SEC filing |
| Mar 28, 2022 | The company announced the departure of Michael Kauffman as Chief Executive Officer in an SEC filing |
| Mar 22, 2022 | The company announced the departure of Michael Kauffman from the board in an SEC filing |
| Mar 2, 2022 | Sohanya Roshan Cheng listed as Chief Commercial Officer (previously SVP Sales & Commercial Ops) in SEC filings |
| Feb 9, 2022 | Sharon Shacham listed as Chief Scientific Officer (previously President & CSO) in SEC filings |
| Dec 3, 2021 | Peter Honig became a director |
| Dec 2, 2021 | The company announced the departure of Mikael Dolsten from the board in an SEC filing |
| Jun 7, 2021 | Sohanya Roshan Cheng became SVP Sales & Commercial Ops |
| Jun 1, 2021 | Michael Mason listed as EVP, CFO & Treasurer (previously SVP, CFO & Treasurer) in SEC filings |
| May 4, 2021 | Richard A. Paulson first listed as President and CEO in an SEC filing |
| Feb 9, 2021 | Tanya Lewis listed as EVP, Chief Reg. Affairs (previously EVP,Chief Reg.&Quality Officer) in SEC filings |
| Feb 9, 2021 | Ran Frenkel listed as EVP, Chief Dev. Officer (previously Chief Dev Operations Officer) in SEC filings |
| Dec 31, 2020 | Stephen Mitchener became SVP, Chief Business Officer |
| Dec 31, 2020 | Michael Mano became SVP, General Counsel&Secretary |
| Nov 25, 2020 | Chen Schor became a director |
| Aug 28, 2020 | Christy J. Oliger became a director |
| Mar 16, 2020 | John Demaree became Chief Commercial Officer |
| Feb 26, 2020 | Richard A. Paulson became a director |
| Oct 30, 2019 | Tanya Lewis became EVP,Chief Reg.&Quality Officer |
| Jul 3, 2019 | Jatin Shah became EVP, Chief Medical Officer |
| Mar 4, 2019 | Wiaczeslaw Smolokowski reported in an SEC filing no longer being a 10% owner |
| Mar 4, 2019 | Marcin Czernik reported in an SEC filing no longer being a 10% owner |
| Mar 4, 2019 | George Hadjimichael reported in an SEC filing no longer being a 10% owner |
| Mar 4, 2019 | Chione Ltd reported in an SEC filing no longer being a 10% owner |
| Mar 4, 2019 | Andreas Hadjimichael reported in an SEC filing no longer being a 10% owner |
| Feb 25, 2019 | Michael Mason became SVP, CFO & Treasurer |
| Jan 18, 2019 | Cameron Peters became VP of Finance |
| Aug 31, 2018 | Carsten Thiel became a director |
| Jun 22, 2018 | Anand Varadan became EVP, Chief Commercial Officer |
| Jan 25, 2018 | Christopher Brett Primiano listed as EVP, CBO, GC & Secretary (previously SVP, Ops, Bus Dev, GC & Sec) in SEC filings |
| Sep 11, 2017 | Michael Falvey became EVP, CFO & Treasurer |
| Apr 3, 2017 | Michael Todisco became VP, Finance & Assistant Treas |
| Jan 24, 2017 | Christopher Brett Primiano listed as SVP, Ops, Bus Dev, GC & Sec (previously Svp,corp Dev,gen Counsel&sec.) in SEC filings |
Not reported recently (15)
- Peter Honig · Last reported as a director in an SEC filing dated May 25, 2023
- Stephen Mitchener · Last reported as SVP, Chief Business Officer in an SEC filing dated Mar 2, 2023
- Ran Frenkel · Last reported as EVP, Chief Dev. Officer in an SEC filing dated Mar 2, 2022
- Jatin Shah · Last reported as EVP, Chief Medical Officer in an SEC filing dated Feb 22, 2022
- Tanya Lewis · Last reported as EVP, Chief Reg. Affairs in an SEC filing dated Mar 1, 2021
- John Demaree · Last reported as Chief Commercial Officer in an SEC filing dated Mar 1, 2021
- Christopher Brett Primiano · Last reported as EVP, CBO, GC & Secretary in an SEC filing dated Dec 3, 2020
- J. Scott Garland · Last reported as a director in an SEC filing dated Jun 7, 2019
- Anand Varadan · Last reported as EVP, Chief Commercial Officer in an SEC filing dated Feb 19, 2019
- Cameron Peters · Last reported as VP of Finance in an SEC filing dated Feb 19, 2019
- Carsten Thiel · Last reported as a director in an SEC filing dated Sep 4, 2018
- Michael Falvey · Last reported as EVP, CFO & Treasurer in an SEC filing dated Jan 25, 2018
- Kenneth E Weg · Last reported as a director in an SEC filing dated Jun 16, 2017
- Michael Todisco · Last reported as VP, Finance & Assistant Treas in an SEC filing dated Apr 10, 2017
- Justin A Renz · Last reported as EVP, CFO & Treasurer in an SEC filing dated Jan 24, 2017
Compiled from SEC filings by the company and its directors and officers. Dates are as stated in those filings. Where no filing says when someone left, we show the last filing that listed them.
ETF Holders
23 ETFs hold KPTI
23 shown · $1.92M total exposure · 0.00% AUM-weighted avg weight
| # | ETF | Provider | Weight | $ Exposure | ETF AUM | As Of |
|---|---|---|---|---|---|---|
| 1 | VTI Vanguard Morningstar Total Stock Market ETF | Vanguard | 0.00% | $826,829 | — | 2026-09-30 |
| 2 | VXF Vanguard Extended Market ETF | Vanguard | 0.00% | $320,962 | — | 2026-09-30 |
| 3 | IWM iShares Russell 2000 ETF | iShares (BlackRock) | 0.00% | $247,429 | $74.6B | 2026-10-23 |
| 4 | VTWO Vanguard Russell 2000 ETF | Vanguard | 0.00% | $140,762 | — | 2026-09-30 |
| 5 | FESM Fidelity Enhanced Small Cap Core ETF | Fidelity | 0.00% | $96,150 | $6.6B | 2026-10-23 |
| 6 | IWN iShares Russell 2000 Value ETF | iShares (BlackRock) | 0.00% | $78,912 | $13.9B | 2026-10-23 |
| 7 | PRFZ Invesco RAFI US 1500 Small-Mid ETF | Nport | 0.00% | $61,795 | — | 2026-07-31 |
| 8 | IWC iShares Micro-Cap ETF | iShares (BlackRock) | 0.00% | $31,680 | $1.2B | 2026-10-23 |
| 9 | QQQS Invesco NASDAQ Future Gen 200 ETF | Invesco | 0.14% | $28,842 | — | 2026-10-24 |
| 10 | TMED T. Rowe Price Health Care ETF | Nport | 0.10% | $24,132 | — | 2026-06-30 |
| 11 | VTWV Vanguard Russell 2000 Value ETF | Vanguard | 0.00% | $19,005 | — | 2026-09-30 |
| 12 | OMFS Invesco Russell 2000 Dynamic Multifactor ETF | Invesco | 0.01% | $18,507 | — | 2026-10-24 |
| 13 | IWO iShares Russell 2000 Growth ETF | iShares (BlackRock) | 0.00% | $14,572 | $13.7B | 2026-10-23 |
| 14 | RSSL Global X Russell 2000 ETF | Global X | 0.00% | $4,681 | — | 2026-10-26 |
| 15 | VTWG Vanguard Russell 2000 Growth ETF | Vanguard | 0.00% | $3,919 | — | 2026-09-30 |
| 16 | VTHR Vanguard Russell 3000 ETF | Vanguard | 0.00% | $2,114 | — | 2026-09-30 |
| 17 | ITWO ProShares Russell 2000 High Income ETF | ProShares | 0.00% | $549 | — | 2026-10-26 |
| 18 | URTY ProShares UltraPro Russell2000 | ProShares | 0.00% | $421 | — | 2026-10-26 |
| 19 | UWM ProShares Ultra Russell2000 | ProShares | 0.00% | $297 | — | 2026-10-26 |
| 20 | FLQS Franklin U.S. Small Cap Multifactor Index ETF | Franklin | 0.00% | $289 | $49.1M | 2026-10-26 |
| 21 | RESM Columbia Research Enhanced Small Cap ETF | Nport | 0.01% | $225 | — | 2026-06-30 |
| 22 | HDG ProShares Hedge Replication ETF | ProShares | 0.00% | $12 | — | 2026-10-26 |
| 23 | RB ProShares Russell 2000 Dynamic Buffer ETF | ProShares | 0.00% | $3 | — | 2026-10-26 |
Fundamentals
Quarterly filings sourced from SEC 10-Q / 10-K reports. TTM tiles aggregate the most recent four quarters; bars show the last ~12 quarters oldest → newest.
Metrics
- Revenue — top-line sales. Look for consistent YoY growth; seasonal businesses need same-quarter comparisons (Q4 '24 vs Q4 '23).
- Net Income — bottom-line profit after all expenses. Can be volatile from one-time items; red bars = net loss.
- Diluted EPS — net income per share assuming options/converts are exercised. Direct input to the P/E ratio.
- Operating Cash Flow — cash generated from core operations, before capex and financing. Harder to manipulate than net income; growing OCF is a quality signal.
How to read the bars
- Sequential growth — quarter-over-quarter trend. Accelerating bars are a momentum signal.
- YoY growth — compare to the same quarter a year earlier to remove seasonality.
- Quality — OCF should roughly track Net Income over time. Large divergence (net income ≫ OCF) flags accruals risk.
- Margins — scan the bar ratios: Net Income / Revenue tells you margin trend without needing a separate chart.
TTM (trailing-twelve-month) smooths seasonality and is used for the P/E calculation. Filings appear 30–90 days after the period closes.
Trailing P/E
—
TTM Diluted EPS
$-13.06
TTM Revenue
$146.62M
TTM Net Income
$-224.74M
TTM Op. Cash Flow
$-65.35M
Quarterly figures (12 quarters)
| Quarter | Period End | Revenue | Net Income | Diluted EPS | Op. Cash Flow |
|---|---|---|---|---|---|
| Q2 '26 | 2026-06-30 | $33.43M | $-67.02M | $-2.32 | $-24.93M |
| Q1 '26 | 2026-03-31 | $35.07M | $-22.39M | $-1.24 | $-22.73M |
| Q4 '25 | 2025-12-31 | $34.08M | $-102.20M | $-7.00 | $-11.83M |
| Q3 '25 | 2025-09-30 | $44.04M | $-33.13M | $-3.82 | $-5.86M |
| Q2 '25 | 2025-06-30 | $37.93M | $-37.25M | $-4.32 | $-18.70M |
| Q1 '25 | 2025-03-31 | $30.02M | $-23.46M | $-2.77 | $-38.98M |
| Q4 '24 | 2024-12-31 | $30.54M | $-30.78M | $-3.60 | $-25.81M |
| Q3 '24 | 2024-09-30 | $38.78M | $-32.07M | $-3.85 | $-19.45M |
| Q2 '24 | 2024-06-30 | $42.79M | $18.25M | $-2.97 | $-38.50M |
| Q1 '24 | 2024-03-31 | $33.13M | $-37.36M | $-4.85 | $-43.73M |
| Q4 '23 | 2023-12-31 | $33.75M | $-41.84M | $-5.40 | $-18.59M |
| Q3 '23 | 2023-09-30 | $36.01M | $-34.51M | $-4.50 | $-29.53M |
Q2 2026 • period ending 2026-06-30 • filed 2026-08-13
Valuation
Ratios derived from TTM financials and the current market price, sampled daily. History chart shows how expensive the stock is today relative to its own recent past.
Price Multiples
- P/E — price / TTM earnings. Rough market rule: 10–15 value, 15–25 market, >30 growth/premium. Negative when earnings are negative.
- P/B — price / book value. Useful for financials and asset-heavy names; meaningless for asset-light software.
- P/S — price / TTM revenue. Useful when earnings are negative or noisy (early-stage growth).
- EV/EBITDA — capital-structure-neutral. <10 cheap, 10–15 reasonable, >20 rich. Good for comparing across leverage profiles.
- EV/Sales — like P/S but accounts for debt + cash. Compare within sector.
Profitability & Yields
- ROE — return on equity. >15% strong, >25% exceptional. Caution: high leverage inflates ROE.
- ROA — return on assets. Leverage-neutral; >5% solid, >10% exceptional.
- Div Yield — annual dividend / price. Compare to 10Y Treasury; sustained yield >6% often signals distress.
- FCF Yield — free cash flow / market cap. >5% is attractive; negative means burning cash.
Balance Sheet
- Debt/Equity — leverage. <1 conservative, >2 aggressive. Sector-dependent (utilities naturally high, tech low).
- Current Ratio — short-term liquidity. >1.5 comfortable, <1 raises short-term solvency flags.
Reading the history chart
- Compare current level to the 3-year band: near the high end = relatively expensive; near the low = relatively cheap.
- Multiples expanding while earnings are flat = sentiment-driven rally.
- Multiples compressing while earnings grow = value coming from fundamentals.
P/E
—
P/B
—
P/S
0.07
EV/EBITDA
—
EV/Sales
1.12
ROE
—
ROA
-201.9%
Div Yield
0.00%
FCF Yield
-675.18%
Debt/Equity
—
Current Ratio
—
Market Cap
$9.68M
as of 2026-10-26
Short Interest & Float
Regulatory short-interest reports publish on a bi-weekly settlement cadence; short-volume is reported daily by the trade-reporting facilities. Float is derived from insider-ownership filings.
Metric definitions
- Short Interest — total shares currently sold short as of the settlement date. Lags real time by ~8 business days.
- SI % of Float — short interest / free float. The key crowding metric.
- Days to Cover — short interest / avg daily volume. How many full trading days it would take shorts to buy back. High DTC + catalyst = squeeze fuel.
- Short Vol Ratio — today's short-sale volume / total volume. Intraday selling pressure proxy (not the same as short interest).
- Free Float — shares available for public trading (total shares minus insider / restricted).
- Float % — free float / shares outstanding. <50% = tightly held, more prone to squeezes.
How to read the signals
- SI % of Float < 5% — typical, no particular signal.
- 5–15% — elevated; watch for catalysts (earnings, guidance, macro).
- 15–30% — heavily shorted; tight-float names in this range have produced notable squeezes historically.
- >30% — extreme; borrow is likely expensive and squeeze risk is material.
- Days to Cover > 5 combined with high SI% amplifies squeeze potential.
History chart
- Trend matters more than level. Rapidly rising short interest often precedes negative catalysts or heavy hedging.
- A sudden drop in SI after a rally may indicate a squeeze in progress.
Short interest is reported mid-month and end-of-month; short volume is daily.
Short Interest
6.06M
SI % of Float
29.16%
Days to Cover
4.79
Short Vol Ratio
52.1%
Free Float
20.77M
Float %
91.6%
Short interest 2026-09-30 • Short volume 2026-10-26 • Float 2026-09-04